PTC in Personalizing Neoadjuvant Therapy for Patients With Advanced Gastrointestinal Tumor

Peking University

Status: Not yet enrolling

Conditions: Gastrointestinal Neoplasms

Treatments: Other: PTC drug screening

Study type: Interventional

Funder types: Other

Identifiers

NCT05280210

PKUCH-PTC

Details and patient eligibility

About

To explore the value of PTC drug screening technique in selecting neoadjuvant therapy for advanced gastrointestinal cancer.

Full description

In this study, patients diagnosed with advanced gastrointestinal cancer including locally advanced gastric cancer, locally advanced colorectal cancer and colorectal cancer with liver metastasis. Tumor sample will be collected by endoscopy biopsy, needle biopsy or surgery, which will used for PTC drug screening.

Patients will be randomized to two groups. Patients in experiment group will receive neoadjuvant therapy based on PTC drug screening, and patients in control group will receive neoadjuvant therapy based on clinical experience. 2-4 cycles of neoadjuvant therapy will be administered. Patients appropriate for surgery will receive radical surgery after neoadjuvant therapy. Pathological response will be compared primarily between these two groups.

This is a randomized controlled, open-label and sequential designed clinical trial. All neoadjuvant therapy used in this study or for PTC drug screening comply with NCCN (National comprehensive cancer network) or CSCO (Chinese Society of Clinical Oncology) guidelines.

Enrollment: 420 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosed of gastrointestinal adenocarcinoma by biopsy
• existence of initially resectable lesions evaluated by investigators
• indications of neoadjuvant chemotherapy including: 1) locally advanced gastric cancer cT1-2N1-3M0 & cT3-4N0-3M0; 2) locally advanced colorectal cancer cT3-4 or N+; 3)colorectal carcinoma with synchronous liver metastases: CRS≤2; 4)other patients who are considered to be appropriate to receive neoadjuvant chemotherapy determined by MDT
• never receive any tumor related treatment including chemotherapy, radiotherapy, and immune therapy
• never diagnosed of other malignancies
• able to tolerate chemotherapy
• ECOG≤2
• life expectance >6 months
• at least 1 measurable lesions(according to RECIST 1.1)
• informed consent

Exclusion criteria

• pregnant or lactating women
• participating in other clinical trials within 6 months
• MSI-H or dMMR or EBER(+)
• lesion located within 10cm from anal margin
• severe liver dysfunction
• severe renal dysfunction
• cognitive disorder, mental disease or poor compliance
• allergic to known chemotherapeutic agents
• other conditions not suitable to participate in this trial determined by investigators

Trial design

Primary purpose: Screening

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

420 participants in 2 patient groups

Neoadjuvant therapy based on PTC drug screening

Experimental group

Description:

Patients will receive neoadjuvant therapy based on PTC drug screening. The regimen is complied with NCCN and CSCO guidelines. PD-1 inhibitor will be used if effective in drug screening.

Treatment:

Other: PTC drug screening

Neoadjuvant therapy based on clinical experience

No Intervention group

Description:

Patients will receive neoadjuvant therapy based on clinical experience. The regimen is complied with NCCN and CSCO guidelines.